Kai Ding to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Kai Ding has written about Neoplasm Recurrence, Local.
Connection Strength
0.491
-
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary. Gynecol Oncol. 2025 Dec; 203:158-164.
Score: 0.195
-
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
Score: 0.153
-
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecol Oncol. 2017 12; 147(3):509-513.
Score: 0.112
-
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 11; 155(2):201-206.
Score: 0.032